Laron syndrome: Difference between revisions
| Line 42: | Line 42: | ||
==[[Laron syndrome diagnosis|Diagnosis]]== | ==[[Laron syndrome diagnosis|Diagnosis]]== | ||
[[Laron syndrome history and symptoms|History and Symptoms]] | [[Laron syndrome physical examination|Physical Examination]] | [[Laron syndrome laboratory findings|Laboratory Findings]] | [[Laron syndrome CT|CT]] | [[Laron syndrome | [[Laron syndrome history and symptoms|History and Symptoms]] | [[Laron syndrome physical examination|Physical Examination]] | [[Laron syndrome laboratory findings|Laboratory Findings]] | [[Laron syndrome CT|CT]] | [[Laron syndrome MRI|MRI]] | [[Laron syndrome echocardiography or ultrasound|Ultrasound]] | [[Laron syndrome other imaging findings|Other Imaging Findings]] | [[Laron syndrome other diagnostic studies|Other Diagnostic Studies]] | ||
==Treatment== | ==Treatment== | ||
Latest revision as of 20:16, 19 September 2012
For patient information click here
| Laron syndrome | |
 | |
|---|---|
| Growth hormone | |
| ICD-10 | E34.3 |
| ICD-9 | 259.4 |
| OMIM | 262500 245590 |
| DiseasesDB | 7262 |
| MeSH | D046150 |
|
Laron syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Laron syndrome On the Web |
|
American Roentgen Ray Society Images of Laron syndrome |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Assosciate Editor(s)-In-Chief: Prashanth Saddala M.B.B.S
Synonyms and keywords: Growth Harmone Receptor Deficiency; Growth hormone insensitivity syndrome; pituitary dwarfism II; Laron syndrome due to postreceptor defect; growth hormone insensitivity due to postreceptor defect; Laron-type dwarfism
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Laron Syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | CT | MRI | Ultrasound | Other Imaging Findings | Other Diagnostic Studies
Treatment
Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies
Case Studies